For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma. The U.S. Food and Drug Adminsitration (FDA) has approved Blenrep (belantamab mafodotin-blmf ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...